

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1 or a full-length complement thereof.
2. **(Currently Amended)** An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, or a full-length complement thereof.
3. **(Canceled)**
4. **(Previously Presented)** An isolated nucleic acid molecule comprising a nucleotide sequence which is at least about 90% homologous to the nucleotide sequence of SEQ ID NO:1 or 3, wherein elevated levels of said nucleic acid molecule are indicative of a malignancy, or a complement thereof.
5. **(Previously Presented)** An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1, 2, 4, 25, 26, 27, 28, 29, 30 or 31 under stringent conditions.
6. **(Previously Presented)** An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1, 2, 4, 25, 26, 27, 28, 29, 30 or 31 and a nucleotide sequence encoding a heterologous polypeptide.
7. **(Previously Presented)** A vector comprising the nucleic acid molecule of any one of claims 1, 2, 4, 25, 26, 27, 28, 29, 30 or 31.
8. **(Original)** The vector of claim 7, which is an expression vector.
9. **(Original)** A host cell transfected with the expression vector of claim 8.

10. **(Original)** A method of producing a polypeptide comprising culturing the host cell of claim 9 in an appropriate culture medium to, thereby, produce the polypeptide.

11-19. **(Canceled)**

20. **(Previously Presented)** A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of any one of claims 1, 2, 4, 25, 26, 27, 28, 29, 30 or 31 and instructions for use.

21-24. **(Canceled)**

25. **(Currently Amended)** An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3 or a full-length complement thereof.

26. **(Currently Amended)** An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:1 or a full-length complement thereof.

27. **(Currently Amended)** An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:3 or a full-length complement thereof.

28. **(Currently Amended)** An isolated nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a full-length complement thereof.

29. **(Previously Presented)** An isolated nucleic acid molecule comprising a nucleotide sequence which is at least about 95% homologous to the nucleotide sequence of SEQ ID NO:1 or 3, wherein elevated levels of said nucleic acid molecule are indicative of a malignancy, or a complement thereof.

30. **(Previously Presented)** A nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 90% homologous to the amino acid sequence

of SEQ ID NO:2, wherein elevated levels of said polypeptide are indicative of a malignancy, or a complement thereof.

31. **(Previously Presented)** A nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 95% homologous to the amino acid sequence of SEQ ID NO:2, wherein elevated levels of said polypeptide are indicative of a malignancy, or a complement thereof.

AMENDMENTS TO THE DRAWINGS

The attached sheet(s) of drawings includes changes to Figures 1-4 in compliance with the Draftsperson's comments in form PTO-948.

Attachment: Replacement sheets (Figures 1-4)